TY - JOUR
T1 - RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMA
AU - Neijt, J. P.
AU - Van Der Burg, M. E L
AU - Vriesendorp, R.
AU - Van Lindert, A. C M
AU - Van Lent, M.
AU - Ten Bokkel Huinink, W. W.
AU - Oosterom, A. T Van
AU - Kooyman, C. D.
AU - Hamerlynck, J. V T H
AU - Houwelingen, J. C Van
AU - Pinedo, H. M.
PY - 1984/9/15
Y1 - 1984/9/15
N2 - 186 patients with advanced epithelial ovarian carcinoma were treated with either a combination of hexamethylmelamine, cyclophosphamide, methotrexate, and 5-fluorouracil (Hexa-CAF) or cyclophosphamide and hexamethylmelamine alternating with doxorubicin and a 5-day course of cisplatin (CHAP-5). Treatment with CHAP-5 resulted in more complete remissions as determined by laparatomy or peritoneoscopy (p = 0·004), better overall response (p = 0·0001), and longer overall survival and progression-free survival (p
AB - 186 patients with advanced epithelial ovarian carcinoma were treated with either a combination of hexamethylmelamine, cyclophosphamide, methotrexate, and 5-fluorouracil (Hexa-CAF) or cyclophosphamide and hexamethylmelamine alternating with doxorubicin and a 5-day course of cisplatin (CHAP-5). Treatment with CHAP-5 resulted in more complete remissions as determined by laparatomy or peritoneoscopy (p = 0·004), better overall response (p = 0·0001), and longer overall survival and progression-free survival (p
UR - http://www.scopus.com/inward/record.url?scp=0021285620&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021285620&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(84)90594-4
DO - 10.1016/S0140-6736(84)90594-4
M3 - Article
C2 - 6147640
AN - SCOPUS:0021285620
SN - 0140-6736
VL - 324
SP - 594
EP - 600
JO - The Lancet
JF - The Lancet
IS - 8403
ER -